Dysgeusia News and Research

RSS
European Medicines Agency accepts Exelixis’ COMETRIQ MAA for review

European Medicines Agency accepts Exelixis’ COMETRIQ MAA for review

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

Timely treatment with Berinert provides faster symptom relief for HAE patients

Timely treatment with Berinert provides faster symptom relief for HAE patients

Meda announces positive results from three MP29-02 studies on allergic rhinitis

Meda announces positive results from three MP29-02 studies on allergic rhinitis

FDA approves CSL Behring's Berinert for treatment of HAE attacks

FDA approves CSL Behring's Berinert for treatment of HAE attacks

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene announces interim results of REVLIMID study on CLL

Celgene announces interim results of REVLIMID study on CLL

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Conference highlights advances in evidence-based integrative therapies for cancer

Conference highlights advances in evidence-based integrative therapies for cancer

New analyses from Phase III studies of VICTRELIS to be presented at AASLD 2011

New analyses from Phase III studies of VICTRELIS to be presented at AASLD 2011

E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug

E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug

Merck secures worldwide rights to vernakalant i.v.

Merck secures worldwide rights to vernakalant i.v.

Roche, Merck sign new non-exclusive agreement for HCV triple combination therapy

Roche, Merck sign new non-exclusive agreement for HCV triple combination therapy

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL